Trial Profile

A Phase I Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN144) With Adjuvant Pembrolizumab for Treatment of Immunotherapy Naïve Patients With High Risk Stage IIIb-dResectable Melanoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lifileucel (Primary) ; Pembrolizumab (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use

05 Jun 2025 Status changed from recruiting to withdrawn prior to enrolment as Iovance withdrew support due to length of time required to meet accrual goal.
05 Dec 2024 Status changed from suspended to recruiting.
07 Aug 2024 Planned initiation date changed to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com